Lifecore Biomedical, Inc. (FRA:LDE)
Germany · Delayed Price · Currency is EUR | Market Cap | 119.06M -45.1% |
| Revenue (ttm) | 110.26M +0.8% |
| Net Income | -29.39M |
| EPS | -0.79 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 70 |
| Open | 3.300 |
| Previous Close | 3.560 |
| Day's Range | 3.300 - 3.300 |
| 52-Week Range | 3.300 - 7.450 |
| Beta | n/a |
| RSI | 16.09 |
| Earnings Date | Mar 16, 2026 |
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk... [Read more]
Financial Performance
In 2025, Lifecore Biomedical's revenue was $129.46 million, an increase of 0.46% compared to the previous year's $128.87 million. Losses were -$34.50 million, -22.22% less than in 2025.
Financial numbers in USD Financial StatementsNews
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System ...
Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company
-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial R...
Lifecore Biomedical Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lifecore Biomedical, Inc. The investigation focuses on Lifecore Biomedica...
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
Lifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call Transcript
Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update
-- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer P...
Lifecore Biomedical to Participate in 6th Annual KeyBanc Capital Markets Healthcare Virtual Forum
CHASKA, Minn., March 10, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical to Report Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, on March 16, 2026
CHASKA, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug B...
Lifecore Biomedical to Participate at DCAT Week 2026
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced ...
Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary d...
Lifecore Biomedical: The Turnaround Is Just Getting Started
Lifecore Biomedical (LFCR) has completed its turnaround, emerging as a pure-play US-based CDMO with a cleaned-up balance sheet and high operational leverage. LFCR's new capacity is underutilized but a...
Lifecore Biomedical to be Added to Nasdaq Biotech Index
CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product
Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference
CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical to Participate in Upcoming Investor Conferences
CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced ...
Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript
Lifecore Biomedical, Inc. ( LFCR) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Parti...
Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update
-- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customer...
Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025
CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company
Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CD...
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced...
Lifecore Biomedical, Inc. (LFCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Paul Josephs - President, CEO & Director Conference ...